IM11 Stock Overview
A medical technology company, manufactures and sells implants for orthopedic surgery.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Implanet S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.081 |
| 52 Week High | €0.21 |
| 52 Week Low | €0.002 |
| Beta | 1.3 |
| 11 Month Change | -13.62% |
| 3 Month Change | 28.89% |
| 1 Year Change | -39.58% |
| 33 Year Change | -90.46% |
| 5 Year Change | -97.49% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| IM11 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -6.7% | -0.2% | -0.5% |
| 1Y | -39.6% | -0.1% | 1.6% |
Return vs Industry: IM11 underperformed the German Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: IM11 underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| IM11 volatility | |
|---|---|
| IM11 Average Weekly Movement | 25.7% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: IM11's share price has been volatile over the past 3 months.
Volatility Over Time: IM11's weekly volatility has decreased from 31% to 26% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 41 | Ludovic Lastennet | www.implanet.com |
Implanet S.A., a medical technology company, manufactures and sells implants for orthopedic surgery. The company offers spinal and knee products. Its products include Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw systems for posterior fixation.
Implanet S.A. Fundamentals Summary
| IM11 fundamental statistics | |
|---|---|
| Market cap | €12.12m |
| Earnings (TTM) | -€6.68m |
| Revenue (TTM) | €7.45m |
1.5x
P/S Ratio-1.7x
P/E RatioIs IM11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IM11 income statement (TTM) | |
|---|---|
| Revenue | €7.45m |
| Cost of Revenue | €4.12m |
| Gross Profit | €3.33m |
| Other Expenses | €10.00m |
| Earnings | -€6.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 10, 2024
| Earnings per share (EPS) | -0.053 |
| Gross Margin | 44.65% |
| Net Profit Margin | -89.65% |
| Debt/Equity Ratio | -3,174.7% |
How did IM11 perform over the long term?
See historical performance and comparison